Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 05, 2020 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001659617 | |
Entity Registrant Name | Moleculin Biotech, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2020 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2020 | |
Document Transition Report | false | |
Entity File Number | 001-37758 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 47-4671997 | |
Entity Address, Address Line One | 5300 Memorial Drive | |
Entity Address, City or Town | Houston | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 77007 | |
City Area Code | 713 | |
Local Phone Number | 300-5160 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | true | |
Entity Shell Company | false | |
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | MBRX | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 62,464,564 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 12,795 | $ 10,735 |
Prepaid expenses and other current assets | 2,455 | 2,749 |
Total current assets | 15,250 | 13,484 |
Furniture and equipment, net | 522 | 316 |
Intangible assets | 11,148 | 11,148 |
Operating lease right-of-use asset | 224 | 287 |
Total assets | 27,144 | 25,235 |
Current liabilities: | ||
Accounts payable | 1,343 | 2,153 |
Accrued expenses and other current liabilities | 2,095 | 1,417 |
Total current liabilities | 3,438 | 3,570 |
Operating lease liability - long-term, net of current portion | 190 | 276 |
Warrant liability - long-term | 9,049 | 5,818 |
Total liabilities | 12,677 | 9,664 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding | 0 | 0 |
Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2020 and December 31, 2019, 61,764,225 and 45,727,700 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively | 62 | 46 |
Additional paid-in capital | 68,649 | 55,055 |
Accumulated other comprehensive income | 33 | 31 |
Accumulated deficit | (54,277) | (39,561) |
Total stockholders’ equity | 14,467 | 15,571 |
Total liabilities and stockholders’ equity | $ 27,144 | $ 25,235 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2020 | Dec. 31, 2019 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 61,764,225 | 45,727,700 |
Common stock, shares outstanding (in shares) | 61,764,225 | 45,727,700 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Revenues | $ 0 | $ 0 | $ 0 | $ 0 |
Operating expenses: | ||||
Research and development | 4,435,000 | 2,785,000 | 10,971,000 | 7,816,000 |
General and administrative | 1,659,000 | 1,672,000 | 5,122,000 | 4,748,000 |
Depreciation and amortization | 57,000 | 51,000 | 154,000 | 147,000 |
Total operating expenses | 6,151,000 | 4,508,000 | 16,247,000 | 12,711,000 |
Loss from operations | (6,151,000) | (4,508,000) | (16,247,000) | (12,711,000) |
Other income: | ||||
Gain from change in fair value of warrant liability | 2,743,000 | 124,000 | 1,489,000 | 3,059,000 |
Other income, net | 10,000 | 5,000 | 32,000 | 5,000 |
Interest income, net | 3,000 | 5,000 | 10,000 | 10,000 |
Net loss before taxes | (3,395,000) | (4,374,000) | (14,716,000) | (9,637,000) |
Income tax benefit | 0 | 229,000 | 0 | 229,000 |
Net loss | $ (3,395,000) | $ (4,145,000) | $ (14,716,000) | $ (9,408,000) |
Net loss per common share - basic and diluted (in dollars per share) | $ (0.06) | $ (0.09) | $ (0.26) | $ (0.24) |
Weighted average common shares outstanding, basic and diluted (in shares) | 61,474,857 | 45,464,746 | 56,979,507 | 39,034,303 |
Net loss | $ (3,395,000) | $ (4,145,000) | $ (14,716,000) | $ (9,408,000) |
Other comprehensive income (loss): | ||||
Foreign currency translation | 10,000 | (3,000) | 2,000 | (16,000) |
Comprehensive loss | $ (3,385,000) | $ (4,148,000) | $ (14,714,000) | $ (9,424,000) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (14,716) | $ (9,408) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 154 | 147 |
Stock-based compensation | 1,265 | 1,155 |
License rights expense settled in stock | 0 | 490 |
Change in fair value of warrant liability | (1,489) | (3,059) |
Operating lease, net of sublease receipts | 90 | (10) |
Changes in operating assets and liabilities: | ||
Prepaid expenses and other current assets | 294 | (2,337) |
Accounts payable | (810) | 1,942 |
Accrued expenses and other current liabilities | 565 | (1,441) |
Net cash used in operating activities | (14,647) | (12,521) |
Cash flows from investing activities: | ||
Purchase of fixed assets | (360) | (42) |
Net cash used in investing activities | (360) | (42) |
Cash flows from financing activities: | ||
Proceeds from exercise of stock options | 0 | 5 |
Proceeds from exercise of warrants | 5 | 1,557 |
Payment of tax liability for vested restricted stock units | (17) | 0 |
Proceeds from sale of common stock, net of issuance costs | 17,077 | 19,292 |
Net cash provided by financing activities | 17,065 | 20,854 |
Effect of exchange rate changes on cash and cash equivalents | 2 | (16) |
Net change in cash and cash equivalents | 2,060 | 8,275 |
Cash and cash equivalents, at beginning of period | 10,735 | 7,134 |
Cash and cash equivalents, at end of period | 12,795 | 15,409 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest | 0 | 1 |
Cash paid for taxes | 20 | 15 |
Research and development expense settled in stock | 0 | 490 |
Non-cash investing and financing activities: | ||
Purchases of property and equipment in accounts payable and accrued liabilities | $ 316 | $ 21 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands | Lincoln Park [Member]Common Stock [Member] | Lincoln Park [Member]Additional Paid-in Capital [Member] | Lincoln Park [Member]Retained Earnings [Member] | Lincoln Park [Member]AOCI Attributable to Parent [Member] | Lincoln Park [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 28,528,663 | |||||||||
Balance at Dec. 31, 2018 | $ 29 | $ 40,564 | $ (26,356) | $ 35 | $ 14,272 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 605,367 | 5,250,000 | ||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 0 | $ 883 | $ 0 | $ 0 | $ 883 | $ 5 | 3,221 | 0 | 0 | 3,226 |
Stock-based compensation | 0 | 348 | 0 | 0 | 348 | |||||
Consolidated net loss | 0 | 0 | (4,041) | 0 | (4,041) | |||||
Foreign currency translation | $ 0 | 0 | 0 | (11) | (11) | |||||
Exercised, number of shares (in shares) | 25,000 | |||||||||
Stock options exercised | $ 0 | 5 | 0 | 0 | 5 | |||||
Balance (in shares) at Mar. 31, 2019 | 34,409,030 | |||||||||
Balance at Mar. 31, 2019 | $ 34 | 45,021 | (30,397) | 24 | 14,682 | |||||
Balance (in shares) at Dec. 31, 2018 | 28,528,663 | |||||||||
Balance at Dec. 31, 2018 | $ 29 | 40,564 | (26,356) | 35 | 14,272 | |||||
Consolidated net loss | (9,408) | |||||||||
Foreign currency translation | (16) | |||||||||
Balance (in shares) at Sep. 30, 2019 | 45,727,700 | |||||||||
Balance at Sep. 30, 2019 | $ 46 | 54,673 | (35,763) | 19 | 18,975 | |||||
Balance (in shares) at Mar. 31, 2019 | 34,409,030 | |||||||||
Balance at Mar. 31, 2019 | $ 34 | 45,021 | (30,397) | 24 | 14,682 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 9,375,000 | |||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 9 | 3,575 | 0 | 0 | 3,584 | |||||
Stock-based compensation | 0 | 318 | 0 | 0 | 318 | |||||
Consolidated net loss | 0 | 0 | (1,221) | 0 | (1,221) | |||||
Foreign currency translation | $ 0 | 0 | 0 | (2) | (2) | |||||
Warrants exercised (in shares) | 1,413,018 | |||||||||
Warrants exercised | $ 2 | 4,729 | 0 | 0 | 4,731 | |||||
Balance (in shares) at Jun. 30, 2019 | 45,197,048 | |||||||||
Balance at Jun. 30, 2019 | $ 45 | 53,643 | (31,618) | 22 | 22,092 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 100,674 | |||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 0 | 52 | 0 | 0 | 52 | |||||
Stock-based compensation | 0 | 489 | 0 | 0 | 489 | |||||
Consolidated net loss | 0 | 0 | (4,145) | 0 | (4,145) | |||||
Foreign currency translation | $ 0 | 0 | 0 | (3) | (3) | |||||
Common stock issued for license rights (in shares) | 429,978 | |||||||||
Common stock issued for license rights | $ 1 | 489 | 0 | 0 | 490 | |||||
Balance (in shares) at Sep. 30, 2019 | 45,727,700 | |||||||||
Balance at Sep. 30, 2019 | $ 46 | 54,673 | (35,763) | 19 | 18,975 | |||||
Balance (in shares) at Dec. 31, 2019 | 45,727,700 | |||||||||
Balance at Dec. 31, 2019 | $ 46 | 55,055 | (39,561) | 31 | 15,571 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 7,500,000 | |||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 7 | 559 | 0 | 0 | 566 | |||||
Stock-based compensation | 0 | 397 | 0 | 0 | 397 | |||||
Consolidated net loss | 0 | 0 | (1,209) | 0 | (1,209) | |||||
Foreign currency translation | $ 0 | 0 | 0 | (33) | (33) | |||||
Balance (in shares) at Mar. 31, 2020 | 53,227,700 | |||||||||
Balance at Mar. 31, 2020 | $ 53 | 56,011 | (40,770) | (2) | 15,292 | |||||
Balance (in shares) at Dec. 31, 2019 | 45,727,700 | |||||||||
Balance at Dec. 31, 2019 | $ 46 | 55,055 | (39,561) | 31 | 15,571 | |||||
Consolidated net loss | (14,716) | |||||||||
Foreign currency translation | $ 2 | |||||||||
Exercised, number of shares (in shares) | 0 | |||||||||
Balance (in shares) at Sep. 30, 2020 | 61,764,225 | |||||||||
Balance at Sep. 30, 2020 | $ 62 | 68,649 | (54,277) | 33 | $ 14,467 | |||||
Balance (in shares) at Mar. 31, 2020 | 53,227,700 | |||||||||
Balance at Mar. 31, 2020 | $ 53 | 56,011 | (40,770) | (2) | 15,292 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 7,170,964 | |||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 7 | 10,000 | 0 | 0 | 10,007 | |||||
Stock-based compensation | 0 | 408 | 0 | 0 | 408 | |||||
Consolidated net loss | 0 | 0 | (10,112) | 0 | (10,112) | |||||
Foreign currency translation | $ 0 | 0 | 0 | 25 | 25 | |||||
Warrants exercised (in shares) | 4,500 | |||||||||
Warrants exercised | $ 0 | 9 | 0 | 0 | 9 | |||||
Balance (in shares) at Jun. 30, 2020 | 60,403,164 | |||||||||
Balance at Jun. 30, 2020 | $ 60 | 66,428 | (50,882) | 23 | 15,629 | |||||
Issued for cash - sale of common stock, net of issuance costs (in shares) | 1,301,126 | |||||||||
Issued for cash - sale of common stock, net of issuance costs | $ 2 | 1,778 | 0 | 0 | 1,780 | |||||
Stock-based compensation | 0 | 460 | 0 | 0 | 460 | |||||
Consolidated net loss | 0 | 0 | (3,395) | 0 | (3,395) | |||||
Foreign currency translation | $ 0 | 0 | 0 | 10 | 10 | |||||
Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) (in shares) | 59,935 | |||||||||
Common stock issued upon vesting of restricted stock units (net of shares withheld for payment of tax liability) | $ 0 | (17) | 0 | 0 | (17) | |||||
Balance (in shares) at Sep. 30, 2020 | 61,764,225 | |||||||||
Balance at Sep. 30, 2020 | $ 62 | $ 68,649 | $ (54,277) | $ 33 | $ 14,467 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands | 3 Months Ended | |||||
Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | |
Issued for cash - sale of common stock, issuance costs | $ 135 | $ 336 | $ 709 | $ 59 | $ 1,300 | $ 617 |
Note 1 - Nature of Business and
Note 1 - Nature of Business and Liquidity | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Nature of Business and Liquidity [Text Block] | 1. The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, February 2019, Core Technologies - two 1 2 STAT3 WP1066 3 WP1122 one 1/2 one 1 WP1066, two 1 WP1220, WP1066 1 The Company refers to Annamycin as a "Next Generation Anthracycline" since it is designed to avoid the multidrug resistance mechanisms that typically defeat currently approved anthracyclines, as well as to be non-cardiotoxic, which is the dose limiting toxicity for all currently approved anthracyclines. Annamycin is currently in a Phase 1/2 1 2020, may first may WP1066 one STAT3, 1 may 1 WP1220 WP1220 The Company is also developing new prodrugs to exploit the potential uses of its WP1122 WP1122, 2 WP1122 2020, third WP1122 Drug Candidates one 1 1/2 2020. 2 RP2D 1/2 fifth 240 mg/m2. second not six second three 210 mg/m2 no sixth 300 mg/m2. 19 In addition to Annamycin, the Company has other drug development projects, two • Two separate Phase 1 WP1066. one no • The Company is also evaluating WP1066 one STAT3 2021. • WP1220 WP1066 2019 1 2 2021 WP1220 • Several molecules in the WP1122 WP1122 WP1122 one may WP1122 Clinical Trials - 1 1/2 fifth 1 2020. In September 2018, WP1066 1 July 2018, April 2020, second 1 August 2019, 1 WP1220, WP1066 WP1220 2 2021 WP1220 Moleculin has recently announced discoveries (both internally funded and independently developed) supporting the potential use of WP1122 19 WP1122 19 may first 2021, may Licenses - no July 2019 no may Independently from potential patent protection, MBI has received Orphan Drug designation (ODD) from the FDA for Annamycin for the treatment of AML and for WP1066 may may seven not 10 may 5 one no April 2019, COVID 19 March 2020, 19 19 19 19, Nasdaq September 30, 2020, 30 $1.00 5550 2 not 5810 3 180 March 29, 2021, March 29, 2021, $1.00 10 10 5810 3 not March 29, 2021, may second 180 may not March 29, 2021 not may no may, no |
Note 2 - Basis of Presentation,
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation – Unaudited Interim Condensed Consolidated Financial Information - 10 8 X. not not December 31, 2019 December 31, 2018 10 March 19, 2020. Principles of consolidation Use of Estimates - may may may Going Concern - September 30, 2020 not September 30, 2020 not not may third Cash and Cash Equivalents three may $250,000. Prepaid Expenses and Other Current Assets - September 30, 2020 December 31, 2019 Vendor prepayments and deposits $ 1,312 $ 1,857 Prepaid insurance 880 352 Other current assets 257 529 Related party receivables 5 10 Non-trade receivables 1 1 Total prepaid expenses and other current assets $ 2,455 $ 2,749 Vendor prepayments at September 30, 2020 December 31, 2019 2020 first 2021 Intangible Assets Property and Equipment, net - September 30, 2020 December 31, 2019 Operating Lease Right-of-Use Asset - may not 12 7 Cost Method Investment - not Fair Value of Financial Instruments - The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three 1 3 Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 Level 2 Level 3 The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September 30, 2020 December 31, 2019 Quoted Prices Significant Significant Liabilities in Active Other Other Measured Markets for Observable Unobservable at Fair Identical Inputs Inputs Description Value Assets (Level 1) (Level 2) (Level 3) Fair value of warrant liability as of September 30, 2020: $ 9,049 $ — $ — $ 9,049 Fair value of warrant liability as of December 31, 2019: $ 5,818 $ — $ — $ 5,818 The table below (in thousands) of Level 3 third third 2020 3 may not not Three Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, June 30, 2020 $ — $ 11,792 $ 11,792 Exercise of warrants — — — Change in fair value - net — (2,743 ) (2,743 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 The table below (in thousands) of Level 3 December 31, 2019 nine September 30, 2020 3 may not not Nine Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, December 31, 2019 $ — $ 5,818 $ 5,818 Issuances of warrants — 4,724 4,724 Exercise of warrants — (4 ) (4 ) Change in fair value - net — (1,489 ) (1,489 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 Loss Per Common Share three September 30, 2020 2019 nine September 30, 2020 2019 Stock-based Compensation 718, 718 718 not January 1, 2020, Subsequent Events - 8 Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 2018 13 2018 13 820, December 15, 2019. January 1, 2020 not In December 2019, No. 2019 12, 740 2019 12 2019 12 first December 15, 2020. In August 2020, No. 2020 06, 470 20 815 40 2020 06 2020 06 December 15, 2021, no December 15, 2020, The Company does not not |
Note 3 - Accrued Expenses and O
Note 3 - Accrued Expenses and Other Current Liabilities | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 3. Accrued expenses and other current liabilities consist of the following components (in thousands): September 30, 2020 December 31, 2019 Accrued chemistry manufacturing and control costs $ 1,086 $ 49 Accrued clinical activities 311 93 Accrued payroll and bonuses 247 436 Operating lease liability - current 114 103 Related party payable 99 99 Accrued license fees and sponsored research agreements 95 201 Accrued legal, regulatory, and professional 87 272 Accrued other 56 164 Total accrued expenses and other current liabilities $ 2,095 $ 1,417 |
Note 4 - Warrants
Note 4 - Warrants | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Warrants Disclosure [Text Block] | 4. At September 30, 2020 December 31, 2019 Number of Shares Under Outstanding Warrants at Number of Shares Under Outstanding Warrants at Weighted Average Exercise Price at Remaining Contractual Life at September 30, 2020 September 30, 2020 December 31, 2019 September 30, 2020 (No. Years) Liability Classified Warrants (1) Issued February 2017 404,002 404,002 $ 1.50 1.4 Issued February 2018 2,273,700 2,273,700 2.80 2.9 Issued June 2018 (2) 742,991 742,991 2.03 3.2 Issued March 2019 1,581,000 1,585,500 1.10 3.5 Issued April 2019 5,250,000 5,250,000 1.75 3.6 Issued February 2020 6,150,000 — 1.05 4.8 16,401,693 10,256,193 $ 1.58 Equity Classified Warrants Issued May 2016 - Bonwick 107,802 107,802 $ 7.50 0.6 Issued July 2017 - Consulting (3) 150,000 150,000 2.61 1.8 Issued April 2018 - Consulting 100,000 100,000 3.00 0.5 Issued August 2019 - Consulting 150,000 150,000 1.64 1.9 Issued April 2020 - Consulting 100,000 — 1.14 4.6 607,802 507,802 $ 3.06 Balance outstanding 17,009,495 10,763,995 $ 1.63 ( 1 may March 2019 February 2017 may February 2017. ( 2 December 22, 2023, June 21, 2023. ( 3 Liability Classified Warrants The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Beginning in 2020, 2019, The assumptions used in determining the fair value of the Company’s outstanding liability classified warrants are as follows: September 30, 2020 December 31, 2019 Risk-free interest rate 0.1% to 0.3% 1.6% to 1.7% Volatility 112.5% to 124.1% 97.5% to 107.5% Expected life (years) 1.4 to 4.9 2.1 to 4.3 Dividend yield —% —% A summary of the Company's liability classified warrant activity during the nine September 30, 2020 Number of Shares Range of Warrant Exercise Weighted Average Weighted Average Remaining Contractual Under Warrant Price per Share Exercise Price Life (Years) Balance at January 1, 2020 10,256,193 $ 1.10 $ 2.80 $ 1.89 4.0 Granted 6,150,000 1.05 1.05 1.05 4.8 Exercised (4,500 ) 1.10 1.10 1.10 — Expired — — — — — Balance at September 30, 2020 16,401,693 $ 1.05 $ 2.80 $ 1.58 3.9 Vested and Exercisable at September 30, 2020 16,401,693 $ 1.10 $ 2.80 $ 1.89 3.9 In connection with the Company's stock offering that closed in February 2020, six five first February 2025. For a summary of the changes in fair value associated with our warrant liability for the nine September 30, 2020 2 Equity Classified Warrants In April 2020, At September 30, 2020 December 31, 2019 The Company recorded zero and $92,000 in stock compensation expense for non-employee consulting agreements for the three September 30, 2020 2019 nine September 30, 2020 2019 September 30, 2020 |
Note 5 - Equity
Note 5 - Equity | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 5. July 2020 In July 2020, 2019 April 2020, 2019 February 2020 In February 2020, 4 nine September 30, 2020 Stock-based Compensation and Outstanding Awards Under the terms of the Company’s 2015 June 2020, 2015 September 30, 2020 2015 Stock-based compensation for the three nine September 30, 2020 2019 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 General and administrative $ 366 $ 430 $ 1,029 $ 1,003 Research and development 94 59 236 152 Total Stock-based Compensation Expense $ 460 $ 489 $ 1,265 $ 1,155 Each of the Company's stock-based compensation arrangements are discussed below. Stock Options Stock option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Stock option awards generally have a 10-year contractual term and vest over a 4-year period for employees and over a 1 to 3-year period for directors from the grant date on a straight-line basis over the requisite service period. The grant-date fair value of stock options is determined using the Black-Scholes option-pricing model. Additionally, the Company’s stock options provide for full vesting of unvested outstanding options, in the event of a change of control of the Company. The fair value of each stock option is estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted below. The expected term of the stock option awards was computed using the “plain vanilla” method as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin 107 not 2020, 2020, The fair value of the option grants has been estimated, with the following weighted-average assumptions: Nine Months Ended September 30, Stock Option Assumptions: 2020 2019 Risk-free interest rate 0.2% to 0.5% 1.0% to 1.3% Expected volatility of common stock 125.4% to 128.0% 85% to 100% Expected life (years) 3.8 to 6.3 5.3 to 6.3 Expected dividend yield —% —% Stock option activity for the nine September 30, 2020 Weighted Average Grant Date Weighted Average Weighted Average Remaining Contractual Aggregate Intrinsic Number of Shares Fair Value Exercise Price Term (in years) Value Outstanding, December 31, 2019 3,836,000 $ 1.59 $ 2.26 8.3 $ — Granted 1,554,750 $ 0.83 $ 0.95 Exercised — $ — $ — Forfeited (20,000 ) $ 0.89 $ 1.06 Outstanding, September 30, 2020 5,370,750 $ 1.37 $ 1.88 8.1 $ — Exercisable, September 30, 2020 1,978,917 $ 1.91 $ 2.79 7.2 $ — Options granted during 2020 September 30, 2020 not nine September 30, 2020 2019 July 2020, August 2020, one October 2020, Restricted Stock Restricted stock units are granted with a grant date fair value determined using the closing price of the Company's common stock on the grant date. Restricted stock units vest annually in four equal installments. Additionally, the Company’s restricted stock unit agreements provide for full vesting of the restricted stock award in the event of a change of control of the Company. Restricted stock unit activity for the nine September 30, 2020 Weighted Average Grant Date Weighted Average Remaining Contractual Number of Shares Fair Value Term (in years) Unvested Shares, December 31, 2019 316,907 $ 1.31 3.5 Granted 353,211 $ 0.93 Vested (79,227 ) $ 1.31 Unvested Shares, September 30, 2020 590,891 $ 1.08 3.3 As of September 30, 2020 not |
Note 6 - Income Taxes
Note 6 - Income Taxes | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not 2020 three nine September 30, 2020 2020 not” not September 30, 2020 The Company recorded an income tax provision of zero and $229,000 for the three nine September 30, 2020 2019 three September 30, 2020 2019 nine September 30, 2020 2019 nine September 30, 2019 June 2018, nine September 30, 2020. no On March 27, 2020, 19 not nine September 30, 2020 may |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 7. In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of September 30, 2020 Lease Obligations Payable During the nine September 30, 2020 not The following summarizes quantitative information about the Company's operating leases for the three nine September 30, 2020 2019 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Lease cost: Operating lease cost $ 29 $ 15 $ 87 $ 31 Short-term lease cost 4 12 13 38 Variable lease cost 7 7 22 19 Total $ 40 $ 34 $ 122 $ 88 The Company recorded approximately $10,000 and $31,000 in sublease income from a related party for the three nine September 30, 2020 Other supplemental cash flow information for operating leases is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 34 $ 20 $ 100 $ 41 Right-of-use assets obtained in exchange for lease liabilities: Operating leases $ — $ 212 $ — $ 321 At September 30, 2020 842 Maturity of lease liabilities As of September 30, 2020 2020 (remaining three months) $ 34 2021 138 2022 105 2023 56 2024 10 2025 and thereafter — Total lease payments 343 Less: imputed interest (39 ) Present value of operating lease liabilities $ 304 As of September 30, 2020 not Licenses MD Anderson - three September 30, 2020 2019 nine September 30, 2020 2019 HPI - March 16, 2020, two first second sixty three September 30, 2020 2019 nine September 30, 2020 2019 Sponsored Research Agreements with MD Anderson - October 2021. three September 30, 2020 2019 nine September 30, 2020 2019 |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 8. In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of our subsequent events occurring after September 30, 2020 2020 July 2020, 2020 may October 2020, 2020 2020 2019 third 2020 November 11, 2020, “2020 “2020 2020 2020 2020 may 2020 Pursuant to the terms of the 2020 2020 2020 2020 may $22.0 On November 12, 2020, 2,829,214 On November 11, 2020, October 4, 2018 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation – Unaudited Interim Condensed Consolidated Financial Information - 10 8 X. not not December 31, 2019 December 31, 2018 10 March 19, 2020. |
Consolidation, Policy [Policy Text Block] | Principles of consolidation |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates - may may may |
Going Concern Policy [Policy Text Block] | Going Concern - September 30, 2020 not September 30, 2020 not not may third |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents three may $250,000. |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible Assets |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment, net - September 30, 2020 December 31, 2019 |
Lessee, Leases [Policy Text Block] | Operating Lease Right-of-Use Asset - may not 12 7 |
Investment, Policy [Policy Text Block] | Cost Method Investment - not |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments - The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three 1 3 Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 Level 2 Level 3 The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 4. The following table provides assets and liabilities reported at fair value and measured on a recurring basis at September 30, 2020 December 31, 2019 Quoted Prices Significant Significant Liabilities in Active Other Other Measured Markets for Observable Unobservable at Fair Identical Inputs Inputs Description Value Assets (Level 1) (Level 2) (Level 3) Fair value of warrant liability as of September 30, 2020: $ 9,049 $ — $ — $ 9,049 Fair value of warrant liability as of December 31, 2019: $ 5,818 $ — $ — $ 5,818 The table below (in thousands) of Level 3 third third 2020 3 may not not Three Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, June 30, 2020 $ — $ 11,792 $ 11,792 Exercise of warrants — — — Change in fair value - net — (2,743 ) (2,743 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 The table below (in thousands) of Level 3 December 31, 2019 nine September 30, 2020 3 may not not Nine Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, December 31, 2019 $ — $ 5,818 $ 5,818 Issuances of warrants — 4,724 4,724 Exercise of warrants — (4 ) (4 ) Change in fair value - net — (1,489 ) (1,489 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 |
Earnings Per Share, Policy [Policy Text Block] | Loss Per Common Share three September 30, 2020 2019 nine September 30, 2020 2019 |
Share-based Payment Arrangement [Policy Text Block] | Stock-based Compensation 718, 718 718 not January 1, 2020, |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events - 8 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In August 2018, No. 2018 13, 820 2018 13 2018 13 820, December 15, 2019. January 1, 2020 not In December 2019, No. 2019 12, 740 2019 12 2019 12 first December 15, 2020. In August 2020, No. 2020 06, 470 20 815 40 2020 06 2020 06 December 15, 2021, no December 15, 2020, The Company does not not |
Note 2 - Basis of Presentatio_2
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | September 30, 2020 December 31, 2019 Vendor prepayments and deposits $ 1,312 $ 1,857 Prepaid insurance 880 352 Other current assets 257 529 Related party receivables 5 10 Non-trade receivables 1 1 Total prepaid expenses and other current assets $ 2,455 $ 2,749 |
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] | Quoted Prices Significant Significant Liabilities in Active Other Other Measured Markets for Observable Unobservable at Fair Identical Inputs Inputs Description Value Assets (Level 1) (Level 2) (Level 3) Fair value of warrant liability as of September 30, 2020: $ 9,049 $ — $ — $ 9,049 Fair value of warrant liability as of December 31, 2019: $ 5,818 $ — $ — $ 5,818 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, June 30, 2020 $ — $ 11,792 $ 11,792 Exercise of warrants — — — Change in fair value - net — (2,743 ) (2,743 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 Nine Months Ended September 30, 2020 Warrant Liability Current Warrant Liability Long-Term Warrant Liability Total Balance, December 31, 2019 $ — $ 5,818 $ 5,818 Issuances of warrants — 4,724 4,724 Exercise of warrants — (4 ) (4 ) Change in fair value - net — (1,489 ) (1,489 ) Balance, September 30, 2020 $ — $ 9,049 $ 9,049 |
Note 3 - Accrued Expenses and_2
Note 3 - Accrued Expenses and Other Current Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | September 30, 2020 December 31, 2019 Accrued chemistry manufacturing and control costs $ 1,086 $ 49 Accrued clinical activities 311 93 Accrued payroll and bonuses 247 436 Operating lease liability - current 114 103 Related party payable 99 99 Accrued license fees and sponsored research agreements 95 201 Accrued legal, regulatory, and professional 87 272 Accrued other 56 164 Total accrued expenses and other current liabilities $ 2,095 $ 1,417 |
Note 4 - Warrants (Tables)
Note 4 - Warrants (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Under Outstanding Warrants at Number of Shares Under Outstanding Warrants at Weighted Average Exercise Price at Remaining Contractual Life at September 30, 2020 September 30, 2020 December 31, 2019 September 30, 2020 (No. Years) Liability Classified Warrants (1) Issued February 2017 404,002 404,002 $ 1.50 1.4 Issued February 2018 2,273,700 2,273,700 2.80 2.9 Issued June 2018 (2) 742,991 742,991 2.03 3.2 Issued March 2019 1,581,000 1,585,500 1.10 3.5 Issued April 2019 5,250,000 5,250,000 1.75 3.6 Issued February 2020 6,150,000 — 1.05 4.8 16,401,693 10,256,193 $ 1.58 Equity Classified Warrants Issued May 2016 - Bonwick 107,802 107,802 $ 7.50 0.6 Issued July 2017 - Consulting (3) 150,000 150,000 2.61 1.8 Issued April 2018 - Consulting 100,000 100,000 3.00 0.5 Issued August 2019 - Consulting 150,000 150,000 1.64 1.9 Issued April 2020 - Consulting 100,000 — 1.14 4.6 607,802 507,802 $ 3.06 Balance outstanding 17,009,495 10,763,995 $ 1.63 |
Schedule of Warrants or Rights, Assumptions Used [Table Text Block] | September 30, 2020 December 31, 2019 Risk-free interest rate 0.1% to 0.3% 1.6% to 1.7% Volatility 112.5% to 124.1% 97.5% to 107.5% Expected life (years) 1.4 to 4.9 2.1 to 4.3 Dividend yield —% —% |
Schedule of Warrant Activity [Table Text Block] | Number of Shares Range of Warrant Exercise Weighted Average Weighted Average Remaining Contractual Under Warrant Price per Share Exercise Price Life (Years) Balance at January 1, 2020 10,256,193 $ 1.10 $ 2.80 $ 1.89 4.0 Granted 6,150,000 1.05 1.05 1.05 4.8 Exercised (4,500 ) 1.10 1.10 1.10 — Expired — — — — — Balance at September 30, 2020 16,401,693 $ 1.05 $ 2.80 $ 1.58 3.9 Vested and Exercisable at September 30, 2020 16,401,693 $ 1.10 $ 2.80 $ 1.89 3.9 |
Note 5 - Equity (Tables)
Note 5 - Equity (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 General and administrative $ 366 $ 430 $ 1,029 $ 1,003 Research and development 94 59 236 152 Total Stock-based Compensation Expense $ 460 $ 489 $ 1,265 $ 1,155 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Nine Months Ended September 30, Stock Option Assumptions: 2020 2019 Risk-free interest rate 0.2% to 0.5% 1.0% to 1.3% Expected volatility of common stock 125.4% to 128.0% 85% to 100% Expected life (years) 3.8 to 6.3 5.3 to 6.3 Expected dividend yield —% —% |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Weighted Average Grant Date Weighted Average Weighted Average Remaining Contractual Aggregate Intrinsic Number of Shares Fair Value Exercise Price Term (in years) Value Outstanding, December 31, 2019 3,836,000 $ 1.59 $ 2.26 8.3 $ — Granted 1,554,750 $ 0.83 $ 0.95 Exercised — $ — $ — Forfeited (20,000 ) $ 0.89 $ 1.06 Outstanding, September 30, 2020 5,370,750 $ 1.37 $ 1.88 8.1 $ — Exercisable, September 30, 2020 1,978,917 $ 1.91 $ 2.79 7.2 $ — |
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] | Weighted Average Grant Date Weighted Average Remaining Contractual Number of Shares Fair Value Term (in years) Unvested Shares, December 31, 2019 316,907 $ 1.31 3.5 Granted 353,211 $ 0.93 Vested (79,227 ) $ 1.31 Unvested Shares, September 30, 2020 590,891 $ 1.08 3.3 |
Note 7 - Commitments and Cont_2
Note 7 - Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Lease, Cost [Table Text Block] | Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Lease cost: Operating lease cost $ 29 $ 15 $ 87 $ 31 Short-term lease cost 4 12 13 38 Variable lease cost 7 7 22 19 Total $ 40 $ 34 $ 122 $ 88 Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 34 $ 20 $ 100 $ 41 Right-of-use assets obtained in exchange for lease liabilities: Operating leases $ — $ 212 $ — $ 321 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Maturity of lease liabilities As of September 30, 2020 2020 (remaining three months) $ 34 2021 138 2022 105 2023 56 2024 10 2025 and thereafter — Total lease payments 343 Less: imputed interest (39 ) Present value of operating lease liabilities $ 304 |
Note 1 - Nature of Business a_2
Note 1 - Nature of Business and Liquidity (Details Textual) | Sep. 30, 2020 |
Number of Core Drug Technologies | 3 |
Number of Drug Candidates | 5 |
Number of Approaches to Treating Cancer of Drug Candidates | 3 |
Animal Life Sciences, Inc [Member] | |
Equity Method Investment, Ownership Percentage | 10.00% |
Note 2 - Basis of Presentatio_3
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies (Details Textual) $ in Thousands, shares in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020USD ($)shares | Sep. 30, 2019shares | Sep. 30, 2020USD ($)shares | Sep. 30, 2019shares | Dec. 31, 2019USD ($) | |
Number of Operating Segments | 1 | ||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (54,277) | $ (54,277) | $ (39,561) | ||
Impairment of Intangible Assets (Excluding Goodwill), Total | 0 | 0 | |||
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance | $ 400 | $ 400 | 300 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares | 22.9 | 14.7 | 20.8 | 11.3 | |
Annamycin [Member] | |||||
Vendor Prepayments and Deposits, Expansion of Production Commitments | $ 1,100 | $ 1,100 | $ 1,500 |
Note 2 - Basis of Presentatio_4
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Vendor prepayments and deposits | $ 1,312 | $ 1,857 |
Prepaid insurance | 880 | 352 |
Other current assets | 257 | 529 |
Related party receivables | 5 | 10 |
Non-trade receivables | 1 | 1 |
Total prepaid expenses and other current assets | $ 2,455 | $ 2,749 |
Note 2 - Basis of Presentatio_5
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Assets and Liabilities at Fair Value Measured on a Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Fair value of warrant liability | $ 9,049 | $ 5,818 |
Fair Value, Inputs, Level 1 [Member] | ||
Fair value of warrant liability | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Fair value of warrant liability | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Fair value of warrant liability | $ 9,049 | $ 5,818 |
Note 2 - Basis of Presentatio_6
Note 2 - Basis of Presentation, Principles of Consolidation and Significant Accounting Policies - Level 3 Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
Sep. 30, 2020 | Sep. 30, 2020 | |
Warrant Liability Current [Member] | ||
Balance | $ 0 | $ 0 |
Exercise of warrants | 0 | 0 |
Change in fair value - net | 0 | 0 |
Issuances of warrants | 0 | |
Balance | 0 | 0 |
Warrant Liability Noncurrent [Member] | ||
Balance | 11,792 | 5,818 |
Exercise of warrants | 0 | (4) |
Change in fair value - net | (2,743) | (1,489) |
Issuances of warrants | 4,724 | |
Balance | 9,049 | 9,049 |
Warrant Liability [Member] | ||
Balance | 11,792 | 5,818 |
Exercise of warrants | 0 | (4) |
Change in fair value - net | (2,743) | (1,489) |
Issuances of warrants | 4,724 | |
Balance | $ 9,049 | $ 9,049 |
Note 3 - Accrued Expenses and_3
Note 3 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2020 | Dec. 31, 2019 |
Accrued chemistry manufacturing and control costs | $ 1,086 | $ 49 |
Accrued clinical activities | 311 | 93 |
Accrued payroll and bonuses | 247 | 436 |
Operating lease liability - current | 114 | 103 |
Related party payable | 99 | 99 |
Accrued license fees and sponsored research agreements | 95 | 201 |
Accrued legal, regulatory, and professional | 87 | 272 |
Accrued other | 56 | 164 |
Total accrued expenses and other current liabilities | $ 2,095 | $ 1,417 |
Note 4 - Warrants (Details Text
Note 4 - Warrants (Details Textual) - USD ($) | Feb. 10, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Apr. 30, 2020 | Dec. 31, 2019 | |
Class of Warrant or Right, Outstanding (in shares) | 17,009,495 | 17,009,495 | 10,763,995 | |||||
Share-based Payment Arrangement, Expense | $ 460,000 | $ 489,000 | $ 1,265,000 | $ 1,155,000 | ||||
Warrants Issued in June 2018 and Expiring December 22, 2023 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 710,212 | 710,212 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.02 | $ 2.02 | ||||||
Warrants Issued in June 2018 and Expiring June 21, 2023 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 32,779 | 32,779 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.32 | $ 2.32 | ||||||
Warrants Issued in July 2017 for Consulting with Exercise Price of 2.41 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 100,000 | 100,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 2.41 | $ 2.41 | ||||||
Warrants Issued in July 2017 for Consulting with Exercise Price 3.00 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 50,000 | 50,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3 | $ 3 | ||||||
Warrants Issued in Connection with the February 2020 Stock Offering [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 5,625,000 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.05 | |||||||
Class of Warrant or Right, Initial Exercise Period (Month) | 6 months | |||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||
Class of Warrant or Right, Outstanding (in shares) | [1] | 6,150,000 | 6,150,000 | 0 | ||||
Oppenheimer Co, Underwriter Warrant [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 525,000 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.05 | |||||||
Warrants Issued in April 2020 for Consulting [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 100,000 | |||||||
Class of Warrant or Right, Vesting Contingency, Research and Development Expenditures Threshold | $ 10,000,000 | |||||||
Class of Warrant or Right, Outstanding (in shares) | 100,000 | 100,000 | 0 | |||||
Equity Classified Warrants [Member] | ||||||||
Class of Warrant or Right, Outstanding (in shares) | 607,802 | 607,802 | 507,802 | |||||
Class of Warrant or Right, Vested and Exercisable (in shares) | 512,802 | 512,802 | 507,802 | |||||
Share-based Payment Arrangement, Expense | $ 0 | $ 92,000 | $ 5,000 | $ 94,000 | ||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 91,000 | $ 91,000 | ||||||
[1] | If the Company subdivides (by any stock split, stock dividend, recapitalization or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased. Also, the Company may voluntarily reduce the warrant exercise price for its warrants issued in March 2019 and February 2017 and may voluntarily extend the contractual term of its warrants issued in February 2017. |
Note 4 - Warrants - Warrants Ou
Note 4 - Warrants - Warrants Outstanding (Details) - $ / shares | 9 Months Ended | 12 Months Ended | |||
Sep. 30, 2020 | Dec. 31, 2019 | Feb. 10, 2020 | |||
Balance outstanding (in shares) | 17,009,495 | 10,763,995 | |||
Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 1.63 | ||||
Warrants Issued in February 2017 [Member] | |||||
Balance outstanding (in shares) | [1] | 404,002 | 404,002 | ||
Balance outstanding, remaining contractual life (Year) | [1] | 1 year 4 months 24 days | |||
Warrants Issued in February 2017 [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1] | $ 1.50 | |||
Warrants Issued in February 2018 [Member] | |||||
Balance outstanding (in shares) | [1] | 2,273,700 | 2,273,700 | ||
Balance outstanding, remaining contractual life (Year) | [1] | 2 years 10 months 24 days | |||
Warrants Issued in February 2018 [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1] | $ 2.80 | |||
Warrants Issued in June 2018 [Member] | |||||
Balance outstanding (in shares) | [1],[2] | 742,991 | 742,991 | ||
Balance outstanding, remaining contractual life (Year) | [1],[2] | 3 years 2 months 12 days | |||
Warrants Issued in June 2018 [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1],[2] | $ 2.03 | |||
Warrants Issued in March 2019 [Member] | |||||
Balance outstanding (in shares) | [1] | 1,581,000 | 1,585,500 | ||
Balance outstanding, remaining contractual life (Year) | [1] | 3 years 6 months | |||
Warrants Issued in March 2019 [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1] | $ 1.10 | |||
Warrants Issued in April 2019 [Member] | |||||
Balance outstanding (in shares) | [1] | 5,250,000 | 5,250,000 | ||
Balance outstanding, remaining contractual life (Year) | [1] | 3 years 7 months 6 days | |||
Warrants Issued in April 2019 [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1] | $ 1.75 | |||
Warrants Issued in Connection with the February 2020 Stock Offering [Member] | |||||
Balance outstanding (in shares) | [1] | 6,150,000 | 0 | ||
Balance outstanding, warrant exercise price (in dollars per share) | $ 1.05 | ||||
Balance outstanding, remaining contractual life (Year) | [1] | 4 years 9 months 18 days | |||
Warrants Issued in Connection with the February 2020 Stock Offering [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [1] | $ 1.05 | |||
Liability Classified Warrants [Member] | |||||
Balance outstanding (in shares) | [1] | 16,401,693 | 10,256,193 | ||
Balance outstanding, remaining contractual life (Year) | 3 years 10 months 24 days | 4 years | |||
Liability Classified Warrants [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 1.58 | [1] | $ 1.89 | ||
Warrants Issued in May 2016 to Bonwick [Member] | |||||
Balance outstanding (in shares) | 107,802 | 107,802 | |||
Balance outstanding, remaining contractual life (Year) | 7 months 6 days | ||||
Warrants Issued in May 2016 to Bonwick [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 7.50 | ||||
Warrants Issued in July 2017 for Consulting [Member] | |||||
Balance outstanding (in shares) | [3] | 150,000 | 150,000 | ||
Balance outstanding, remaining contractual life (Year) | [3] | 1 year 9 months 18 days | |||
Warrants Issued in July 2017 for Consulting [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | [3] | $ 2.61 | |||
Warrants Issued in April 2018 for Consulting [Member] | |||||
Balance outstanding (in shares) | 100,000 | 100,000 | |||
Balance outstanding, remaining contractual life (Year) | 6 months | ||||
Warrants Issued in April 2018 for Consulting [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 3 | ||||
Warrants Issued in August 2019 for Consulting [Member] | |||||
Balance outstanding (in shares) | 150,000 | 150,000 | |||
Balance outstanding, remaining contractual life (Year) | 1 year 10 months 24 days | ||||
Warrants Issued in August 2019 for Consulting [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 1.64 | ||||
Warrants Issued in April 2020 for Consulting [Member] | |||||
Balance outstanding (in shares) | 100,000 | 0 | |||
Balance outstanding, remaining contractual life (Year) | 4 years 7 months 6 days | ||||
Warrants Issued in April 2020 for Consulting [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 1.14 | ||||
Equity Classified Warrants [Member] | |||||
Balance outstanding (in shares) | 607,802 | 507,802 | |||
Equity Classified Warrants [Member] | Weighted Average [Member] | |||||
Balance outstanding, warrant exercise price (in dollars per share) | $ 3.06 | ||||
[1] | If the Company subdivides (by any stock split, stock dividend, recapitalization or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased. Also, the Company may voluntarily reduce the warrant exercise price for its warrants issued in March 2019 and February 2017 and may voluntarily extend the contractual term of its warrants issued in February 2017. | ||||
[2] | Includes warrants to purchase 710,212 shares at an exercise price of $2.02, expiring December 22, 2023, and warrants to purchase 32,779 shares at an exercise price of $2.32, expiring June 21, 2023. | ||||
[3] | Includes warrants to purchase 100,000 shares at an exercise price of $2.41 and warrants to purchase 50,000 shares at an exercise price of $3.00. |
Note 4 - Warrants - Assumptions
Note 4 - Warrants - Assumptions Used (Details) - Liability Classified Warrants [Member] | Sep. 30, 2020 | Dec. 31, 2019 |
Measurement Input, Expected Dividend Rate [Member] | ||
Warrants, assumptions | 0 | 0 |
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants, assumptions | 0.001 | 0.016 |
Minimum [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants, assumptions | 1.125 | 0.975 |
Minimum [Member] | Measurement Input, Expected Term [Member] | ||
Warrants, assumptions | 1.4 | 2.1 |
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants, assumptions | 0.003 | 0.017 |
Maximum [Member] | Measurement Input, Price Volatility [Member] | ||
Warrants, assumptions | 1.241 | 1.075 |
Maximum [Member] | Measurement Input, Expected Term [Member] | ||
Warrants, assumptions | 4.9 | 4.3 |
Note 4 - Warrants - Warrant Act
Note 4 - Warrants - Warrant Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2020 | Dec. 31, 2019 | |||
Balance, number of shares under warrants (in shares) | 10,763,995 | |||
Balance, number of shares under warrants (in shares) | 17,009,495 | 10,763,995 | ||
Weighted Average [Member] | ||||
Balance, warrant exercise price (in dollars per share) | $ 1.63 | |||
Liability Classified Warrants [Member] | ||||
Balance, number of shares under warrants (in shares) | [1] | 10,256,193 | ||
Balance, weighted average remaining contractual life (Year) | 3 years 10 months 24 days | 4 years | ||
Granted, number of shares under warrants (in shares) | 6,150,000 | |||
Granted, weighted average remaining contractual life (Year) | 4 years 9 months 18 days | |||
Exercised, number of shares under warrants (in shares) | (4,500) | |||
Expired, number of shares under warrants (in shares) | 0 | |||
Balance, number of shares under warrants (in shares) | [1] | 16,401,693 | 10,256,193 | |
Vested and Exercisable, number of shares under warrants (in shares) | 16,401,693 | |||
Vested and Exercisable, weighted average remaining contractual life (Year) | 3 years 10 months 24 days | |||
Liability Classified Warrants [Member] | Minimum [Member] | ||||
Balance, warrant exercise price (in dollars per share) | $ 1.10 | |||
Granted, warrant exercise price (in dollars per share) | 1.05 | |||
Exercised, warrant exercise price (in dollars per share) | 1.10 | |||
Expired, warrant exercise price (in dollars per share) | 0 | |||
Balance, warrant exercise price (in dollars per share) | 1.05 | $ 1.10 | ||
Vested and Exercisable, warrant exercise price (in dollars per share) | 1.10 | |||
Liability Classified Warrants [Member] | Maximum [Member] | ||||
Balance, warrant exercise price (in dollars per share) | 2.80 | |||
Granted, warrant exercise price (in dollars per share) | 1.05 | |||
Exercised, warrant exercise price (in dollars per share) | 1.10 | |||
Expired, warrant exercise price (in dollars per share) | 0 | |||
Balance, warrant exercise price (in dollars per share) | 2.80 | 2.80 | ||
Vested and Exercisable, warrant exercise price (in dollars per share) | 2.80 | |||
Liability Classified Warrants [Member] | Weighted Average [Member] | ||||
Balance, warrant exercise price (in dollars per share) | 1.89 | |||
Granted, warrant exercise price (in dollars per share) | 1.05 | |||
Exercised, warrant exercise price (in dollars per share) | 1.10 | |||
Expired, warrant exercise price (in dollars per share) | 0 | |||
Balance, warrant exercise price (in dollars per share) | 1.58 | [1] | $ 1.89 | |
Vested and Exercisable, warrant exercise price (in dollars per share) | $ 1.89 | |||
[1] | If the Company subdivides (by any stock split, stock dividend, recapitalization or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased. Also, the Company may voluntarily reduce the warrant exercise price for its warrants issued in March 2019 and February 2017 and may voluntarily extend the contractual term of its warrants issued in February 2017. |
Note 5 - Equity (Details Textua
Note 5 - Equity (Details Textual) $ / shares in Units, $ in Thousands | Feb. 10, 2020USD ($)$ / sharesshares | Oct. 30, 2020shares | Aug. 31, 2020shares | Jul. 31, 2020USD ($)$ / sharesshares | Apr. 30, 2020USD ($)$ / sharesshares | Sep. 30, 2020USD ($)shares | Sep. 30, 2019USD ($) | Jun. 15, 2018shares |
Proceeds from Issuance of Common Stock | $ 17,077 | $ 19,292 | ||||||
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Aggregate Fair Value | 1,300 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 1,200 | $ 1,000 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 1,349,750 | 1,554,750 | ||||||
Director [Member] | Subsequent Event [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 40,000 | |||||||
Company Founder and Chair of Scientific Advisory Board [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | shares | 100,000 | |||||||
Share-based Payment Arrangement, Option [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 3,000 | |||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 7 months 24 days | |||||||
Share-based Payment Arrangement, Option [Member] | Employees [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | |||||||
Share-based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||||
Share-based Payment Arrangement, Option [Member] | Director [Member] | Minimum [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 1 year | |||||||
Share-based Payment Arrangement, Option [Member] | Director [Member] | Maximum [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||||
Restricted Stock Units (RSUs) [Member] | ||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 600 | |||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years 3 months 18 days | |||||||
Share Based Compensation Arrangement by Share Based Payment Award, Number of Installment Periods | 4 | |||||||
The 2015 Stock Plan [Member] | ||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | shares | 10,500,000 | |||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | shares | 4,409,132 | |||||||
Warrants Issued in Connection with the February 2020 Stock Offering [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 5,625,000 | |||||||
The 2019 ATM Agreement [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 1,301,126 | 7,170,964 | ||||||
Shares Issued, Average Price Per Share (in dollars per share) | $ / shares | $ 1.47 | $ 1.44 | ||||||
Proceeds from Issuance of Common Stock | $ 1,900 | $ 10,300 | ||||||
Payments of Stock Issuance Costs | $ 100 | $ 300 | ||||||
February 2020 Stock Offering [Member] | ||||||||
Stock Issued During Period, Shares, New Issues (in shares) | shares | 7,500,000 | |||||||
Payments of Stock Issuance Costs | $ 700 | |||||||
Shares and Warrants Issued in Period, Purchase Price Per Share and Related Warrant (in dollars per share) | $ / shares | $ 0.80 | |||||||
Proceeds from Issuance or Sale of Equity, Total | $ 6,000 |
Note 5 - Equity - Stock-based C
Note 5 - Equity - Stock-based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Stock-based compensation expense | $ 460 | $ 489 | $ 1,265 | $ 1,155 |
General and Administrative Expense [Member] | ||||
Stock-based compensation expense | 366 | 430 | 1,029 | 1,003 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | $ 94 | $ 59 | $ 236 | $ 152 |
Note 5 - Equity - Assumptions U
Note 5 - Equity - Assumptions Used (Details) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Expected dividend yield | 0.00% | 0.00% |
Minimum [Member] | ||
Risk-free interest rate | 0.20% | 1.00% |
Expected volatility of common stock | 125.40% | 85.00% |
Expected life (years) (Year) | 3 years 9 months 18 days | 5 years 3 months 18 days |
Maximum [Member] | ||
Risk-free interest rate | 0.50% | 1.30% |
Expected volatility of common stock | 128.00% | 100.00% |
Expected life (years) (Year) | 6 years 3 months 18 days | 6 years 3 months 18 days |
Note 5 - Equity - Stock Option
Note 5 - Equity - Stock Option Activity (Details) - USD ($) | 1 Months Ended | 9 Months Ended | 12 Months Ended |
Jul. 31, 2020 | Sep. 30, 2020 | Dec. 31, 2019 | |
Outstanding, number of shares (in shares) | 3,836,000 | ||
Outstanding, weighted average grant date fair value (in dollars per share) | $ 1.59 | ||
Outstanding, weighted average exercise price (in dollars per share) | $ 2.26 | ||
Outstanding, weighted average remaining contractual term (Year) | 8 years 1 month 6 days | 8 years 3 months 18 days | |
Outstanding, aggregate intrinsic value | $ 0 | $ 0 | |
Granted, number of shares (in shares) | 1,349,750 | 1,554,750 | |
Granted, weighted average grant date fair value (in dollars per share) | $ 0.83 | ||
Granted, weighted average exercise price (in dollars per share) | $ 0.95 | ||
Exercised, number of shares (in shares) | 0 | ||
Exercised, weighted average grant date fair value (in dollars per share) | $ 0 | ||
Exercised, weighted average exercise price (in dollars per share) | $ 0 | ||
Forfeited, number of shares (in shares) | (20,000) | ||
Forfeited, weighted average grant date fair value (in dollars per share) | $ 0.89 | ||
Forfeited, weighted average exercise price (in dollars per share) | $ 1.06 | ||
Outstanding, number of shares (in shares) | 5,370,750 | 3,836,000 | |
Outstanding, weighted average grant date fair value (in dollars per share) | $ 1.37 | $ 1.59 | |
Outstanding, weighted average exercise price (in dollars per share) | $ 1.88 | $ 2.26 | |
Exercisable, number of shares (in shares) | 1,978,917 | ||
Exercisable, weighted average grant date fair value (in dollars per share) | $ 1.91 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ 2.79 | ||
Exercisable, weighted average remaining contractual term (Year) | 7 years 2 months 12 days | ||
Exercisable, aggregate intrinsic value | $ 0 |
Note 5 - Equity - Restricted St
Note 5 - Equity - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Unvested Shares, number of shares (in shares) | 316,907 | |
Unvested Shares, weighted average grant date fair value (in dollars per share) | $ 1.31 | |
Unvested Shares, weighted average remaining contractual term (Year) | 3 years 3 months 18 days | 3 years 6 months |
Granted, number of shares (in shares) | 353,211 | |
Granted, weighted average grant date fair value (in dollars per share) | $ 0.93 | |
Vested, number of shares (in shares) | (79,227) | |
Vested, weighted average grant date fair value (in dollars per share) | $ 1.31 | |
Unvested Shares, number of shares (in shares) | 590,891 | 316,907 |
Unvested Shares, weighted average grant date fair value (in dollars per share) | $ 1.08 | $ 1.31 |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Income Tax Expense (Benefit), Total | $ 0 | $ (229,000) | $ 0 | $ (229,000) |
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% | 5.20% | 0.00% | 1.40% |
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | $ 0 |
Note 7 - Commitments and Cont_3
Note 7 - Commitments and Contingencies (Details Textual) | Mar. 16, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) |
Sublease Income | $ 10,000 | $ 31,000 | |||
Operating Lease, Weighted Average Remaining Lease Term (Year) | 2 years 8 months 12 days | 2 years 8 months 12 days | |||
Operating Lease, Weighted Average Discount Rate, Percent | 9.60% | 9.60% | |||
Research and Development Expense, Total | $ 4,435,000 | 2,785,000 | $ 10,971,000 | $ 7,816,000 | |
Houston Pharmaceuticals, Inc [Member] | |||||
Related Party Transaction, Expenses from Transactions with Related Party | 59,000 | 0 | 226,000 | 75,000 | |
Houston Pharmaceuticals, Inc [Member] | Consulting Agreement on Licensed Molecules [Member] | |||||
Other Commitments, Number of Agreements | 2 | ||||
Other Commitment, Total | $ 43,500 | ||||
Houston Pharmaceuticals, Inc [Member] | Agreement Providing Access to Laboratory Equipment [Member] | |||||
Other Commitment, Total | $ 15,000 | ||||
Other Commitments, Cancellation Period (Day) | 60 days | ||||
MD Anderson [Member] | |||||
License Agreements Expense | 61,000 | 60,000 | 183,000 | 180,000 | |
Research and Development Expense, Total | $ 212,000 | $ 177,000 | $ 537,000 | $ 366,000 |
Note 7 - Commitments and Cont_4
Note 7 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Operating lease cost | $ 29 | $ 15 | $ 87 | $ 31 |
Short-term lease cost | 4 | 12 | 13 | 38 |
Variable lease cost | 7 | 7 | 22 | 19 |
Total | 40 | 34 | 122 | 88 |
Operating cash flows from operating leases | 34 | 20 | 100 | 41 |
Right-of-use assets obtained in exchange for lease liabilities operating leases | $ 0 | $ 212 | $ 0 | $ 321 |
Note 7 - Commitments and Cont_5
Note 7 - Commitments and Contingencies - Future Minimum Liabilities (Details) $ in Thousands | Sep. 30, 2020USD ($) |
2020 (remaining three months) | $ 34 |
2021 | 138 |
2022 | 105 |
2023 | 56 |
2024 | 10 |
2025 and thereafter | 0 |
Total lease payments | 343 |
Less: imputed interest | (39) |
Present value of operating lease liabilities | $ 304 |
Note 8 - Subsequent Events (Det
Note 8 - Subsequent Events (Details Textual) - USD ($) | Nov. 12, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Jul. 31, 2020 |
Proceeds from Issuance of Common Stock | $ 17,077,000 | $ 19,292,000 | |||||||||
Stock Issued During Period, Value, New Issues | $ 1,780,000 | $ 10,007,000 | $ 566,000 | $ 52,000 | $ 3,584,000 | $ 3,226,000 | |||||
Lincoln Park [Member] | |||||||||||
Stock Issued During Period, Value, New Issues | $ 883,000 | ||||||||||
Subsequent Event [Member] | Lincoln Park [Member] | |||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,829,214 | ||||||||||
Purchase Agreement, Common Stock, Maximum Aggregate Commitment | $ 22 | ||||||||||
Stock Issued During Period, Shares, Commitment Consideration (in shares) | 760,194 | ||||||||||
Purchase Agreement, Maximum Aggregate Commitment, Number of Additional Shares Issued (in shares) | 304,077 | ||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.707 | ||||||||||
Stock Issued During Period, Value, New Issues | $ 2,000,000 | ||||||||||
Stock Issued During Period, Shares, Additional Commitment Shares (in shares) | 27,643 | ||||||||||
The 2020 ATM Agreement [Member] | |||||||||||
At Market Issuance Sales Agreement, Maximum Aggregate Offering Price | $ 15,000,000 | ||||||||||
The 2020 ATM Agreement [Member] | Subsequent Event [Member] | |||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 700,339 | ||||||||||
Shares Issued, Average Price Per Share (in dollars per share) | $ 0.83 | ||||||||||
Proceeds from Issuance of Common Stock | $ 600,000 | ||||||||||
At Market Issuance Sales Agreement, Commission Fee, Percentage of Gross Proceeds | 3.00% |